Ignite Creation Date:
2024-05-05 @ 11:56 PM
Last Modification Date:
2024-10-26 @ 10:41 AM
Study NCT ID:
NCT01450176
Status:
COMPLETED
Last Update Posted:
2014-01-09
First Post:
2011-10-07
Brief Title:
Comparing Patient Satisfaction With Pataday or Bepreve
Sponsor:
McCabe Vision Center
Organization:
McCabe Vision Center
Study Overview
Official Title:
Comparing Patient Satisfaction Throughout the Day With PATADAY OLOPATADINE HYDROCHLORIDE 02 QD or BEPREVE BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 15 BID
Status:
COMPLETED
Status Verified Date:
2014-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare patient satisfaction with Pataday Olopatadine hydrochloride 02 one daily QD and Bepreve Bepotastine besilate ophthalmic solution 15 two times a day BID
Detailed Description:
5 week randomized study with 15 subjects using Pataday qd for 2 weeks and the other 15 subjects using Bepreve BID for 2 weeks Following a one-week washout period the two groups are given the opposite test article TA for 2 weeks Subjects to complete daily diary regarding effects of drug and are seen in clinic for 3 exams
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 3776-001 | REGISTRY | Sterling IRB | None |